Home About Merus Management Board of Directors Careers Technology Pipeline Publications Investors Contact Human Biclonics® for Superior Clinical Efficacy Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. <!DOCTYPE html><html lang="en" data-cast-api-enabled="true" dir="ltr"> THE BICLONICS® TECHNOLOGY PLATFORM Biclonics® retain the format of antibodies that are produced naturally by the immune system, retaining their favorable attributes including stability and predictability during manufacturing and long half-life and low immunogenicity during treatment of patients. Learn more about our technology PIPELINE Our pipeline comprises Biclonics® for solid and hematological tumors that target combinations of growth factor receptors and immunomodulatory molecules. See what's in our pipeline PARTNERING We make our technologies available in partnerships based on promising target combinations. Please contact us for further information. NEWS Merus to Participate in the BIO Investor Forum on 10 October, 2017 at 8:06 pm Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology on 20 September, 2017 at 11:31 am Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress on 19 September, 2017 at 8:05 pm Merus to Participate in Two Investor Conferences in September 2017 on 30 August, 2017 at 11:01 am Merus to Present at the 2017 Wedbush PacGrow Healthcare Conference on 9 August, 2017 at 11:00 am © 2017 Merus Yalelaan 62 | 3584 CM Utrecht | The Netherlands | T +31 (0)30 253 88 00 | enquiries@merus.nl Design by Scicomvisuals & OVERHAUS